Optiscan reveals InVue real-time imaging device for precision surgery

Optiscan Imaging (ASX: OIL) has revealed the InVue microscopic medical imaging device, designed to benefit the surgical market by providing real-time digital pathology access to surgeons.

The Australian-made device was developed in partnership with local product development company Design + Industry for use in a wide range of clinical settings including cancer diagnosis and treatment.

It aims to put digital pathology directly into the hands of surgeons as they operate, enabling on-the-spot decision making, treatment adjustments and precision surgery.

Real-time imaging

Current pathology workflows are conducted within dedicated laboratories using time-consuming analogue approaches away from the operating theatre that require multiple procedures and provide surgeons with results only after significant time delays.

By comparison, InVue can deliver real-time microscopic imaging and pathology detail to surgeons, which will assist in improving the accuracy of their diagnoses and reduce the need for multiple diagnostic procedures and repeat surgeries.

The device is also expected to help lower healthcare costs and improve patient outcomes.

InVue technology

InVue is Digital Imaging and Communications in Medicine-compliant and Picture Archiving and Communication System-enabled.

It is designed to integrate with Optiscan’s cloud-based telepathology platform to be launched next year.

The platform will help surgeons and pathologists to collaborate on surgical cases in real-time from anywhere in the world.

Digital pathology insights

Optiscan managing director Dr Camile Farah said the new product was a milestone development for the company.

“This paves the way for a significant evolution of digital pathology and precision surgery,” she said.

“It will bring digital pathology insights into the operating theatre and directly into the hands of surgeons, resulting in enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes.”

“We are particularly excited by what this will mean for cancer patients as it facilitates a dramatic step forward in the way cancer can be diagnosed and treated with unprecedented accuracy and precision.”

Breast cancer use

Dr Farah said the first intended use of InVue would be for breast cancer surgery and margin determination.

Breast cancer is the most commonly diagnosed cancer among Australian women, with over 20,000 new cases diagnosed each year.

This number is as high as 300,000 per year in the US, making it an “important and large” addressable market.

“Diagnostic pathology is such a critical component in the surgical treatment of cancer and for so long it has been disconnected from this process,” Dr Farah said.

“InVue brings pathology and surgery together in the operating theatre to enhance the capabilities of both and ultimately facilitate faster and more accurate patient care.”